文献速递肿瘤 PET/CT

前列腺癌患者18F-前列腺特异性膜抗原PET/CT偶然发现并存转移性胰腺癌

Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients With Prostate Cancer on 18 F-Prostate-Specific Membrane Antigen PET/CT.
PubMed 文献 · Clin Nucl Med · 2022-07-15

一例79岁转移性去势抵抗性前列腺癌患者,基线PSMA PET/CT示骨病变,接受阿比特龙联合泼尼松治疗。4个月后随访18F-DCFPyL PET/CT示新发及增多的多灶性PSMA摄取骨和肝病变,而PSA稳定于3.1 ng/mL,肝活检示胰腺腺泡细胞癌转移;回顾性分析两扫描均可见PSMA摄取的胰体病变。

要点

  • 前列腺癌PSMA PET/CT随访中新发肝、骨PSMA摄取而PSA稳定时,应警惕第二原发肿瘤。
  • 肝活检证实为胰腺腺泡细胞癌转移,回顾性阅片两扫描均见胰体PSMA摄取。
  • 胰腺内任何高于背景的PSMA摄取均需怀疑恶性肿瘤。

核心结论

  • 胰腺内任何高于背景的PSMA摄取均需怀疑恶性肿瘤。

研究设计与样本

  • 单个病例报告:79岁转移性去势抵抗性前列腺癌患者,PSA 3.2 ng/mL,基线PSMA PET/CT示PSMA摄取骨病变后接受阿比特龙联合泼尼松治疗,4个月后随访18F-DCFPyL PET/CT并行肝病变活检。

主要发现

  • 4个月后随访18F-DCFPyL PET/CT示新发及增多的多灶性PSMA摄取骨和肝病变,而PSA稳定于3.1 ng/mL。
  • 肝病变活检示原发胰腺腺泡细胞癌转移。
  • 回顾性分析两扫描均可见PSMA摄取的胰体病变。

临床怎么用

  • 原文结论指出胰腺内任何高于背景的PSMA摄取均需怀疑恶性肿瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 79-year-old man with rising prostate-specific antigen of 3.2 ng/mL and diagnosis of metastatic castration-resistant prostate cancer received abiraterone and prednisone for treatment regarding prostate-specific membrane antigen (PSMA)-avid bone lesions on PET/CT. Four months later, a follow-up 18 F-DCFPyL PET/CT demonstrated new and increased multifocal PSMA-avid osseous and liver lesions, whereas prostate-specific antigen was stabled at 3.1 ng/mL. Biopsy of liver lesion showed metastasis from a primary pancreatic acinar cell carcinoma. Retrospectively, PSMA-avid pancreatic body lesion was identified on both PSMA PET/CT scans. This case illustrated that any above background PSMA uptake in the pancreas warrants suspicion for malignancy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lu Y, Li C. Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients With Prostate Cancer on 18 F-Prostate-Specific Membrane Antigen PET/CT. Clin Nucl Med. 2022. PMID: 35835124. doi:10.1097/RLU.0000000000004338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。